What Are Myeloid Blasts and What Do High Counts Mean?

Myeloid blasts are the earliest, most immature cells in the bone marrow’s production line for white blood cells. In a healthy person, they make up a small fraction of bone marrow cells, typically under 5 percent, and rarely show up in the bloodstream at all. When a blood test or bone marrow exam reveals a high blast count, it usually signals that something has gone wrong with the normal process of blood cell development, and the concern at the top of the list is acute myeloid leukemia (AML). But the picture is more layered than “high blasts equals cancer,” and the specific percentage, the genetic features of those blasts, and even how they are counted all shape what a high number actually means for a given person.

Where Myeloid Blasts Come From

All blood cells trace back to hematopoietic stem cells in the bone marrow. These stem cells give rise to progressively more specialized daughter cells. The myeloid branch of this family tree produces granulocytes (like neutrophils) and monocytes, which are key players in the immune system’s front-line defense against infection. The commitment to either of these cell types is controlled by specific transcription factors and signaling molecules called colony-stimulating factors, which guide a cell from its blast stage through intermediate steps to a fully mature, functional cell that gets released into the bloodstream.¹

A myeloid blast, then, is a cell near the very beginning of that journey. It has not yet acquired the specialized equipment of a mature neutrophil or monocyte. Under a microscope, blasts look distinctive: they tend to be larger than mature cells, with a high ratio of nucleus to surrounding cytoplasm and fine, open-looking chromatin in their nuclei. These features reflect a cell that is still actively dividing and has not yet packed itself with the granules and enzymes a mature immune cell needs to do its job.

In normal bone marrow, a small pool of blasts is always present because the body constantly replenishes its short-lived mature blood cells. Blasts divide, differentiate into intermediate forms, mature fully, and leave the marrow. The process is tightly regulated so that blasts never accumulate. When that regulation breaks down, blasts pile up rather than maturing, and that accumulation is the hallmark of several serious blood disorders.

Why Blasts Accumulate in Leukemia

The defining problem in AML is not that blast cells divide at some extraordinary speed. The core issue is that they fail to differentiate. Early research using radioactive labeling showed that leukemic blasts actually have a slower proliferation rate than normal marrow precursors. Many leukemic blasts die, but the ones that survive persist as immature cells that keep dividing without ever maturing into functional blood cells. Over time, these undifferentiated blasts crowd out normal marrow cells, which continue their usual course of maturation and leave the marrow as finished products. The net effect is a bone marrow increasingly dominated by useless blast cells and a bloodstream depleted of the mature cells the body needs.²

The traditional view held that differentiation was completely blocked in AML, but more recent work has complicated that picture. Research has shown that differentiation in AML is not entirely shut off; some leukemic blasts do manage to mature partially or even fully, depending on the specific genetic mutations driving the disease.³ This matters because some newer treatments work precisely by nudging leukemic cells to resume differentiation rather than simply killing them outright.

The 20 Percent Threshold and Its Complications

For decades, the World Health Organization defined AML as having 20 percent or more blasts in the bone marrow or peripheral blood. That cutoff distinguishes AML from myelodysplastic syndromes (MDS), a group of conditions where blast counts are elevated but stay below 20 percent. MDS can be serious on its own, but crossing the 20 percent line has historically been the dividing point for a diagnosis of outright leukemia, with different treatment implications.

Studies have validated this threshold in various clinical settings. In patients with myelofibrosis, for example, the 20 percent circulating blast cutoff reliably distinguished patients in blast-phase disease from those with chronic-phase disease that happened to have elevated blasts in the 5 to 19 percent range. Patients who crossed that 20 percent line had distinctly worse outcomes, supporting the threshold’s prognostic value.⁴

However, the 20 percent rule has become less absolute than it used to be. Updated classification systems now recognize that certain genetic abnormalities are so strongly associated with AML biology that the disease can be diagnosed even when blast counts fall below 20 percent. The two major classification frameworks, the 2022 WHO classification and the International Consensus Classification (ICC), handle this differently. The ICC requires at least 10 percent blasts for most AML subtypes, while the WHO 2022 system does not specify a blast cutoff for several genetically defined AML categories. Both still require more than 20 percent blasts for certain entities, including AML with specific mutations like those involving BCR::ABL1 or CEBPA.⁵ The practical takeaway is that blast percentage alone does not make the diagnosis anymore; genetics now share the driver’s seat.

Not Every Elevated Blast Count Means Cancer

A finding of increased blasts on a blood smear or bone marrow exam can be alarming, but there are non-malignant explanations. One well-documented cause is growth factor therapy. Patients receiving colony-stimulating factors, sometimes given to boost blood cell production after chemotherapy or for other conditions, can develop a marked but temporary increase in both bone marrow and circulating blasts. In reported cases, the blast surge was dramatic enough to mimic acute leukemia or suggest progression of a pre-existing MDS. Critically, the blasts decreased once the growth factor was stopped.⁶

Severe infections, recovery from bone marrow suppression, and certain autoimmune conditions can also push blast counts above normal. These reactive increases tend to be modest and self-limiting, but they can create diagnostic confusion, especially if a patient already has a blood disorder being monitored. This is why a single elevated blast count on a blood test almost always prompts repeat testing and further workup rather than an immediate leukemia diagnosis.

How Blasts Are Counted and Identified

Counting blasts sounds straightforward, but it is one of the trickier tasks in hematology. The standard approach involves a bone marrow aspirate, where liquid marrow is drawn through a needle, and a trephine biopsy, where a small core of bone and marrow tissue is removed. Blasts are then counted on stained smears from the aspirate and, often, on tissue sections from the biopsy.

These two methods do not always agree. One study examining the relationship found that while there is a linear correlation between biopsy and smear blast counts, the total concordance when classifying blasts into clinically meaningful categories (below 5 percent, 5 to 9 percent, 10 to 19 percent, and 20 percent or above) was about 76 percent. When the two methods disagreed, selecting the higher of the two percentages gave the best prognostic prediction for distinguishing MDS from AML.⁷

Even among experienced pathologists, blast counting has variability. Research comparing four experienced hematopathologists found that while their counts were reproducible among themselves, the smear and biopsy counts for the same patient correlated poorly with each other. Both methods showed a tendency to overestimate blasts relative to a digital reference standard, with biopsy evaluations showing a higher positive bias.⁸ Since a difference of a few percentage points around the 20 percent threshold can change a diagnosis, this imprecision is more than academic. It means borderline cases often need careful correlation of morphology, flow cytometry, and genetic testing to reach the right conclusion.

Flow cytometry adds an important layer. This technology identifies cells by the surface markers they carry, and while no single marker can reliably distinguish a leukemic blast from a normal one, combinations of multiple markers can separate the two populations.⁹ This distinction matters for diagnosis, for monitoring treatment response, and for detecting minimal amounts of residual disease after therapy.

Diseases That Drive Blast Counts Up

The most common malignant cause of a high myeloid blast count is AML itself, which can arise on its own (de novo) or evolve from a pre-existing condition like MDS or a myeloproliferative neoplasm. The accumulation of blasts in AML results from acquired genetic mutations that disrupt normal differentiation and give the abnormal cells a survival advantage.³

Chronic myeloid leukemia (CML) is another route to high blast counts, though it takes a different path. Most CML patients live normal lives on targeted therapy with tyrosine kinase inhibitors, but some progress to what is called blast phase, where the disease transforms into something resembling acute leukemia. Blast-phase CML has a particularly poor prognosis, with median survival usually under one year.¹⁰

When blast counts are extremely high, the sheer volume of cells in the bloodstream can cause a dangerous condition called leukostasis. This tends to happen when the white blood cell count exceeds 100,000 per microliter, a situation known as hyperleukocytosis. The sticky, immature blast cells can clog small blood vessels, particularly in the lungs and brain, causing respiratory distress, confusion, or stroke-like symptoms. Managing this medical emergency involves rapidly reducing the blast count while carefully monitoring for complications like tumor lysis syndrome, where the sudden destruction of large numbers of cells floods the body with their contents.¹¹ Patients presenting with very high leukocyte counts also face a higher risk of early hemorrhagic death during the initial days of chemotherapy, even before the platelet count drops dangerously low.¹²

Genetics Matter More Than the Blast Count Alone

Once AML is diagnosed, the blast percentage itself tells you less about prognosis than the genetic makeup of those blasts. The European LeukemiaNet (ELN) risk classification system sorts AML patients into favorable, intermediate, and adverse risk groups based on chromosomal abnormalities and specific gene mutations. In one cohort, three-year overall survival ranged from about 68 percent in the favorable group to roughly 23 percent in the adverse group.¹³

The 2022 update to the ELN system expanded the list of mutations that place a patient in the adverse category. Mutations in genes associated with myelodysplasia, including BCOR, EZH2, SF3B1, SRSF2, STAG2, U2AF1, and ZRSR2, were added alongside previously recognized adverse markers. Patients carrying these myelodysplasia-related mutations without favorable genetic features had a complete remission rate of only about 43 percent and a five-year disease-free survival rate of just 5 percent. But when those same mutations occurred alongside favorable genetic markers, the picture changed dramatically: complete remission rates rose to about 73 percent and five-year survival to roughly 39 percent.¹⁴

Whether AML arises de novo or evolves from a prior blood disorder used to be considered independently prognostic. More recent analysis of large patient cohorts suggests that disease origin (de novo versus secondary) does not carry independent prognostic weight once the ELN 2022 genetic risk and TP53 mutation status are accounted for.¹⁵ In other words, the genetics driving the blasts tell a more complete story than the clinical history leading up to them.

Treatment Once Blasts Are High

For younger, fit patients with newly diagnosed AML, standard front-line treatment remains intensive induction chemotherapy. The backbone regimen, known as “7+3,” involves seven days of continuous cytarabine infusion combined with three days of an anthracycline. The goal is to wipe out the leukemic blasts and allow normal marrow to recover, a state called complete remission.¹⁶

Older adults face a harder calculus. Intensive chemotherapy carries significant risks of treatment-related death, and roughly only 30 percent of patients aged 65 and older are considered eligible for it. For those who are not, lower-intensity options like hypomethylating agents (azacitidine and decitabine) have shown the ability to reduce blast counts and improve outcomes with less toxicity.¹⁷ In recent years, the combination of a hypomethylating agent with venetoclax, a targeted drug, has become a standard approach for older or less fit patients and has significantly improved response rates compared to hypomethylating agents alone.

Allogeneic stem cell transplant remains the most effective way to prevent relapse in intermediate and adverse-risk AML. In one study, transplant improved three-year overall survival from about 34 percent to 63 percent in intermediate-risk patients and from about 10 percent to 46 percent in adverse-risk patients.¹³ The decision of whether and when to transplant depends heavily on the genetic risk profile, the patient’s fitness, and the depth of remission achieved.

Tracking Blasts After Treatment

Achieving a blast count below 5 percent in the bone marrow is the traditional definition of complete remission, but clinicians now know that even patients who meet this threshold can harbor tiny populations of residual leukemic cells. Detecting this measurable residual disease (MRD) has become a major focus in AML management. The technologies used include flow cytometry, which identifies blast cells by their surface markers, and molecular methods like PCR and next-generation sequencing, which look for specific genetic mutations or fusion genes associated with the patient’s leukemia.¹⁸

No current MRD test is perfect. An ideal test would distinguish between residual cells that will cause relapse and those that will not. In practice, most tests detect very low levels of abnormal cells without being able to predict with certainty whether those cells will expand back into full-blown disease. The exception is PCR testing in acute promyelocytic leukemia (APL), a specific AML subtype, where the test reliably predicts relapse risk. For other AML subtypes, MRD results are used alongside clinical and genetic factors to guide decisions about further treatment, including whether to proceed to transplant.

Pediatric Versus Adult AML

AML in children is a biologically different disease from AML in adults, even though both involve accumulating myeloid blasts. Pediatric AML has a lower number of mutations per case, averaging about 5 per sample compared to 10 to 13 in adults. Children are also more likely to have chromosomal rearrangements and less likely to have a normal karyotype. Only about 20 percent of pediatric AML patients have a normal karyotype, whereas the rate is much higher in adults.¹⁹

The epigenetic landscape, meaning the chemical modifications that influence which genes are turned on or off, also differs substantially between pediatric and adult AML. These differences help explain why some treatments work better in children and why the prognostic weight of certain mutations shifts with age. Children with AML generally have better overall survival rates than adults, partly because they tolerate intensive chemotherapy better and partly because the biology of their disease tends to be more treatment-responsive.

Artificial Intelligence in Blast Counting

One of the practical limitations in blast counting is that it depends on a human expert looking through a microscope and categorizing hundreds of cells. This is time-consuming and, as noted earlier, subject to variability. Artificial intelligence systems are beginning to address this. One study evaluated an AI cytomorphology system against expert manual counts in patients with AML and found that the AI achieved about 90 percent accuracy in identifying blast cells, with a sensitivity of roughly 86 percent and a specificity of 98 percent. The correlation between AI blast percentages and expert-determined percentages was strong, both at diagnosis and during post-treatment monitoring.²⁰

The 98 percent specificity is particularly relevant because it means the system rarely called a non-blast cell a blast, which reduces the risk of false alarms that could lead to unnecessary biopsies or treatment changes. These tools are not replacing pathologists yet, but they are increasingly being tested as a screening layer that could speed up diagnosis, improve consistency across laboratories, and flag cases that need closer expert review. For patients in resource-limited settings where experienced hematopathologists are scarce, AI-assisted blast counting could meaningfully improve access to accurate diagnosis.